Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) A compound of Formula **I**:



I

or a pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are independently H or C_{1-4} alkyl, or R^1 and R^2 together form the alkyl ring of a proline or homoproline residue;

R^3 is selected from the group consisting of a side chain of an amino acid and a first fluorophore;

R^4 is H or CH_3;

R^5 is H, an amine protecting group, an amino acid residue, a polypeptide, a peptide which contains a second fluorophore, a chemical moiety bound to a solid support, or a moiety containing from about 1 to about 50 non-hydrogen atoms;

R^6 is an isoleucine side chain or a valine side chain;

W is O or NH;

X is O [[or NH]]; and

Y is H or a hydroxyl protecting group;

Z is C(O) or C(O)-CH(CH_3)-C(O);

provided that [[if]] <u>when</u> R^1 and R^2 together form the alkyl ring of a proline residue, <u>then</u> R^4 is [[methyl]] <u>H</u>~~, and X is O, then R^3 is naphthylmethyl~~.

2. (Currently Amended) The compound according to claim 1 having the formula



or a pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are independently H or C_{1-4} alkyl, or R^1 and R^2 together form the alkyl ring of a proline residue;

R^3 is selected from the group consisting of a side chain of an amino acid and a first fluorophore;

R^4 is H or CH_3;

R^5 is H, an amine protecting group, an amino acid residue, a polypeptide, a peptide which contains a second fluorophore, a chemical moiety bound to a solid support, or a moiety containing from about 1 to about 50 non-hydrogen atoms;

R^6 is an isoleucine side chain or a valine side chain;

X is O [[or NH]]; and

Y is H or a hydroxyl protecting group;

provided that [[if]] when R^1 and R^2 together form the alkyl ring of a proline residue, then R^4 is [[methyl]] H~~, and X is O, then R^3 is naphthylmethyl~~.

3. (Original) The compound according to claim 2, wherein R^1 is H and R^2 is methyl.

4. (Original; Withdrawn) The compound according to claim 2, wherein R^1 and R^2 are methyl.

5. (Original; Withdrawn) The compound according to claim 2, wherein R^1 and R^2 together form the alkyl ring of a proline residue.

6. (Original; Withdrawn) The compound according to claim 2, wherein R^3 is a side chain of an amino acid.

7. (Original; Withdrawn) The compound according to claim 2, wherein R^3 is naphtylmethyl.

8. (Original) The compound according to claim 2, wherein R^3 is a benzyl group optionally substituted with OH, OCH_3, $CO(C_6H_5)$, F, Cl, Br, I, CH_3, or C_2H_5.

9. (Original; Withdrawn) The compound according to claim 2, wherein R^3 contains a fluorophore.

10. (Original) The compound according to claim 2, wherein R^4 is CH_3.

11. (Original; Withdrawn) The compound according to claim 2, wherein R^4 is H.

12. (Original; Withdrawn) The compound according to claim 2, wherein R^5 is H.

13. (Original; Withdrawn) The compound according to claim 2, wherein R^5 is an amine protecting group.

14. (Original) The compound according to claim 2, wherein R^5 is an amino acid residue or a polypeptide.

15. (Original; Withdrawn) The compound according to claim 2, wherein R^5 contains a fluorophore.

16. (Original) The compound according to claim 2, wherein R^5 is selected from the group consisting of -(*N*-methyl)leucine;

-(*N*-methyl)leucine-proline;

-(*N*-CBz-*N*-methyl)leucine;

-(*N*-methyl)leucine-proline-lactate;

-(*N*-methyl)leucine-proline-pyruvate;

-(*N*-methyl)leucine-proline-lactate-glutamine-pyroglutamate;

-(*N*-methyl)leucine-proline-lactate-glutamine-cyclopentanoate;

-(*N*-methyl)leucine-proline-lactate-leucine-pyroglutamate;

-(*N*-methyl)leucine-proline-lactate-glutamine-cyclopentanoate;

-(*N*-methyl)leucine-proline-alanine-leucine-pyroglutamate, and

-(*N*-methyl)leucine-proline-(*N*-methyl)alanine-leucine-pyroglutamate.

17. (Original) The compound according to claim 2, wherein R^6 is a valine side chain.

18. (Original; Withdrawn) The compound according to claim 2, wherein R^6 is a leucine side chain.

19. (Original) The compound according to claim 2, wherein Y is H.

20. (Original; Withdrawn) The compound according to claim 2, wherein Y is a hydroxyl protecting group.

21-22. (Cancelled)

23. (Original; Withdrawn) The compound according to claim 2, wherein R^1 and R^2 together form the alkyl ring of a proline residue; R^3 is a benzyl group optionally substituted with one or more selected from the group consisting of OH, OCH_3, $CO(C_6H_5)$, F, Cl, Br, I, CH_3, and C_2H_5; R^4 is H; R^6 is a valine side chain; X is O; and Y is H.

24. (Original) The compound according to claim 2, wherein R^1 is H; R^2 is CH_3; R^3 is a benzyl group optionally substituted with one or more selected from the group consisting of OH, OCH_3, $CO(C_6H_5)$, F, Cl, Br, I, CH_3, and C_2H_5; R^4 is CH_3; R^5 is as defined above; R^6 is a valine side chain; X is O; and Y is H.

25. (Original; Withdrawn) The compound according to claim 2, wherein R^1 is CH_3; R^2 is CH_3; R^3 is a benzyl group optionally substituted with one or more selected from the group consisting of OH, OCH_3, $CO(C_6H_5)$, F, Cl, Br, I, CH_3, and C_2H_5, preferably OCH_3; R^4 is CH_3; R^6 is a valine side chain; X is O; and Y is H.

26. (Cancelled)

27. (Original) The compound according to claim 2, wherein R^5 consists of 1-5 amino acid residues.

28. (Currently Amended; Withdrawn) The compound according to claim 2, having the structure



or a pharmaceutically acceptable salt thereof.

29. (Currently Amended; Withdrawn) The compound according to claim 2, having the structure



or a pharmaceutically acceptable salt thereof.

30. (Currently Amended) The compound according to claim 2, having the structure



or a pharmaceutically acceptable salt thereof.

31. (Currently Amended) The compound according to claim 2, having the structure



or a pharmaceutically acceptable salt thereof.

32. (Cancelled)

33. (Currently Amended; Withdrawn) A compound having the structure



or a pharmaceutically acceptable salt thereof.

34. (Previously Presented) A composition comprising a compound according to claim 1 and a pharmaceutically compatible excipient or carrier.

35. (Previously Presented; Withdrawn) A method of inhibiting, treating, or preventing tumorigenesis, comprising contacting a cell with an effective amount of a compound according to claim 1.

36. (Previously Presented; Withdrawn) A method of preventing or inhibiting the growth of a cancer cell, comprising contacting a cancer cell with an effective amount of a compound according to claim 1.

37. (Previously Presented; Withdrawn) A method of inhibiting or preventing protein synthesis, comprising contacting a cell or cellular component with an effective amount of a compound of claim 1.

38. (Previously Presented; Withdrawn) A method of enhancing apoptosis, comprising contacting a cell or cellular component with an effective amount of a compound according to claim 1.

39. (Previously Presented; Withdrawn) A method of providing immunosuppresive therapy, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.